The IMID Forum

Join Professor Iain McInnes and Doctor Philip Mease for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, they examine key findings from studies by Fleischmann et al. and Nozaki et al. discussing the long-term effectiveness and safety of advanced targeted therapies for RA.

Join Professor Peter Nash from the Griffith University in Brisbane, and Laura Coates, Professor at the University of Oxford’s Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, as they discuss a recent paper ‘Ixekizumab with tirzepatide achieved greater disease control than ixekizumab alone in adults with psoriatic arthritis and overweight or obesity: Results from a randomized clinical trial’.

Join Dr Sofia Ramiro and Professor Atul Deodhar as they discuss the top publications in the world of axSpA. This month, the conversation covered the long-term safety and efficacy of bimekizumab and ixekizumab in r-axSpA.

Join Professor Peter Nash from the Griffith University in Brisbane, and Dr Murat Torgutalp, from the Charité – Universitätsmedizin in Berlin, as they discuss his recent paper ‘Frequency and characteristics of axial involvement in psoriatic arthritis: Results from the International Multicentre AXIS Study’.

Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review two recent studies by Etani et al. and George et al. that examine the infectious complications associated with immunosuppressive therapy in rheumatoid arthritis, including herpes zoster risk across five JAK inhibitors and the relationship between RA treatments and nonserious infections.

Join Professor Peter Nash from the Griffith University in Brisbane, and Doctor Chung-Mao Kao from Taichung Veterans General Hospital, as they discuss the recent publication ‘Malignancy risk in patients with rheumatoid arthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: A 5-year population-based cohort study’.

Join Professor Laura Coates and Professor Philip Mease as they discuss a recent publication examining minimal clinically important improvement thresholds in psoriatic arthritis. This month’s conversation explores how patients with differing levels of baseline disease activity may require different degrees of improvement before perceiving treatment benefit, highlighting the potential for more personalised treatment targets and shared decision making in PsA.

Join Professors Xenofon Baraliakos, Laura Coates and Dr Sofia Ramiro as they break down the top RA, PsA and axSpA abstracts, sessions and posters from this year's EULAR conference.

Join Professor Sofia Ramiro as she summarises her top RA, PsA and axSpA abstracts, posters, and presentations for Day 4 of EULAR 2026 (Saturday, June 6th).

Join Professor Sofia Ramiro as she summarises her top RA, PsA and axSpA abstracts, posters, and presentations for Day 3 of EULAR 2026 (Friday, June 5th).